| Literature DB >> 33610142 |
Berrin Papila Kundaktepe1, Ali Vedat Durgun1, Ertuğrul Göksoy1, Salih Pekmezci1, Metin Kapan2, Kaya Sarıbeyoğlu3, Mehmet Velidedeoğlu1, Mehmet Eliçevik4.
Abstract
Background and aim: Vascular variations of grafts are handled with various reconstruction techniques in renal transplantation. We aimed to analyze the effects of these reconstruction techniques and sites on patient/graft outcomes. Materials and methods: Renal transplantation cases at the Transplantation Unit of the General Surgery Department, İstanbul Uni- versity Cerrahpaşa Medical Faculty between January 1st, 2000 and December 31st, 2012 were analyzed retrospectively. Postoperative duplex ultrasound results, urea-creatinine reduction rates, and complications were evaluated.Entities:
Keywords: Renal transplantation; anastomosis; complication; graft vascular variation
Mesh:
Substances:
Year: 2021 PMID: 33610142 PMCID: PMC8283428 DOI: 10.3906/sag-2007-285
Source DB: PubMed Journal: Turk J Med Sci ISSN: 1300-0144 Impact factor: 0.973
Evaluation of anastomosis types according to demographic features.
| Anastomosis type | p | |||||||
|---|---|---|---|---|---|---|---|---|
| 1External iliac artery end-to-side (n = 45) | 2Internal iliacartery end-to-side (n = 152) | •Internal iliac artery end-to-end (n = 3) | •Common iliac artery end-to-side (n = 3) | 3External iliac artery end-to-side, two arteries(n = 15) | 4Internal iliacartery end-to-end, two arteries(n = 10) | |||
| Age (year) | Q1 - Q3 (Median) | 28.5 - 50.5 (40) | 31 - 42 (35) | 39 - 54 (54) | 57 - 60 (58) | 32 - 50 (37) | 28.5 - 39.8 (34.5) | a0.269 |
| Mean ± SD | 40.64 ± 12.69 | 37.17 ± 9.82 | 49.00 ± 8.66 | 58.33 ± 1.53 | 40.73 ± 11.40 | 35.50 ± 8.76 | ||
| Gender; n (%) | Female | 15 (33.3) | 48 (31.6) | 0 (0) | 1 (33.3) | 5 (33.3) | 4 (40.0) | c0.938 |
| Male | 30 (66.7) | 104 (68.4) | 3 (100) | 2 (66.7) | 10 (66.7) | 6 (60.0) | ||
| Donors; n (%) | Mothers | 17 (37.8) | 68 (44.7) | 0 (0) | 0 (0) | 7 (46.7) | 4 (40.0) | d0.849 |
| Fathers | 6 (13.3) | 36 (23.7) | 0 (0) | 0 (0) | 3 (20.0) | 4 (40.0) | c0.235 | |
| Siblings | 9 (20) | 28 (18.4) | 0 (0) | 0 (0) | 1 (6.7) | 1 (10.0) | c0.723 | |
| Spouses | 10 (22.2) | 16 (10.5) | 3 (100) | 3 (100) | 4 (26.7) | 0 (0) | c0.048* | |
| Nonblood relativesof the patients | 1 (2.2) | 1 (0.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | c0.531 | |
| Second-degreerelatives | 2 (4.4) | 3 (2.0) | 0 (0) | 0 (0) | 0 (0) | 1 (10.0) | c0.217 | |
| Early complications;n (%) | Complications ( - ) | 34 (75.6) | 113 (74.3) | 2 (66.7) | 3 (100) | 10 (66.7) | 7 (70.0) | c0.855 |
| Complications ( + ) | 11 (24.4) | 39 (25.7) | 1 (33.3) | 0 (0) | 5 (33.3) | 3 (30.0) | ||
| Late complications;n (%) | Complications ( - ) | 33 (73.3) | 122 (80.3) | 2 (66.7) | 2 (66.7) | 10 (66.7) | 5 (50.0) | c0.095 |
| Complications ( + ) | 12 (26.7) | 30 (19.7) | 1 (33.3) | 1 (33.3) | 5 (33.3) | 5 (50.0) | ||
aKruskal–Wallis test cFisher–Freeman–Halton–Exact test dPearson Ki-kare test
The comparison of the anastomosis sites in the living-donor group (external/common iliac artery and internal iliac artery) without taking the graft renal arterial status into consideration.
| Anastomosis type | gp | ||||
|---|---|---|---|---|---|
| Total (n = 228) | External or Common iliac artery (n = 51) | Internal iliac artery(n = 177) | |||
| Day 1 urea (mg/dL) | Q1-Q3 (Median) | 51–93.8 (66) | 49–94 (68) | 51–93.5 (64) | 0.951 |
| Mean ± SD | 74.62 ± 33.90 | 74.14 ± 33.06 | 74.76 ± 34.23 | ||
| Day 7 urea (mg/dL) | Q1 - Q3 (Median) | 46.3–96.8 (68) | 42–91 (60) | 47.5–101.5 (70) | 0.056 |
| Mean ± SD | 84.09 ± 57.02 | 69.43 ± 40.8 | 88.32 ± 60.34 | ||
| Day 30 urea (mg/dL) | Q1 - Q3 (Median) | 39–63 (50) | 38–63 (50) | 40v 63 (50) | 0.751 |
| Mean ± SD | 55.36 ± 26,74 | 54.69 ± 26.57 | 55.56 ± 26.87 | ||
| Month 6 urea (mg/dL) | Q1 - Q3 (Median) | 31–46.5 (37) | 32–49 (41) | 31–46 (36) | 0.098 |
| Mean ± SD | 39.68 ± 13.25 | 41.43 ± 12.92 | 39.17 ± 13.34 | ||
| Year 1 urea (mg/dL) | Q1 - Q3 (Median) | 30v 45 (38) | 32–48 (40) | 29–45 (37) | 0.162 |
| Mean ± SD | 39.49 ± 13.84 | 41.14 ± 13.47 | 39.01 ± 13.95 | ||
| Day 1 creatinine(mg/dL) | Q1 - Q3 (Median) | 2.4–4.9 (3,3) | 2–4 (3.2) | 2.4–5.1 (3.4) | 0.048* |
| Mean ± SD | 3.97 ± 2.34 | 3.28 ± 1.52 | 4.16 ± 2.50 | ||
| Day 7 creatinine(mg/dL) | Q1 - Q3 (Median) | 1.2–2.3 (1.5) | 1.1–1.6 (1.3) | 1.3–2.6 (1.7) | 0.001** |
| Mean ± SD | 2.36 ± 2.27 | 1.63 ± 1.14 | 2.57 ± 2.47 | ||
| Day 30 creatinine(mg/dL) | Q1 - Q3 (Median) | 1–1.6 (1.3) | 0.9–1.4 (1.2) | 1–1.6 (1.3) | 0.071 |
| Mean ± SD | 1.42 ± 0.99 | 1.24 ± 0.34 | 1.47 ± 1.10 | ||
| Month 6 creatinine(mg/dL) | Q1 - Q3 (Median) | 1.1–1.5 (1.3) | 1–1.4 (1.3) | 1.1–1.5 (1.3) | 0.347 |
| Mean ± SD | 1.31 ± 0.35 | 1.24 ± 0.30 | 1.33 ± 0.37 | ||
| Year 1 creatinine(mg/dL) | Q1 - Q3 (Median) | 1.1–1.5 (1.3) | 1–1.4 (1.2) | 1.1–1.5 (1.3) | 0.057 |
| Mean ± SD | 1.31 ± 0.45 | 1.20 ± 0.34 | 1.34 ± 0.47 | ||
| Renal artery blood flow velocity (cm/sec) | Q1 - Q3 (Median) | 115–196.6 (135.3) | 113.5–233 (140) | 115–186.3 (133.5) | 0.722 |
| Mean ± SD | 172.88 ± 95.47 | 178.56 ± 98.73 | 170.92 ± 94.68 | ||
| Resistive Index | Q1 - Q3 (Median) | 0.6–0.7 (0.6) | 0.6–0.7 (0.6) | 0.6–0.7 (0.6) | 0.765 |
| Mean ± SD | 0.64 ± 0.1 | 0.64 ± 0.12 | 0.64 ± 0.09 | ||
gMann–Whitney U Test
The comparison of the anastomosis sites in the living-donor group, taking into consideration the type of the anastomosis and the arterial status of the graft separately. *Statistically significant.
| Anastomosis type | ap | Post Hoc;bp | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1External iliac artery end-to-side (n = 45) | 2Internal iliac artery end-to-side (n = 152) | •Internal iliac artery end-to-end (n = 3) | •Common iliac artery end-to-side (n = 3) | 3External iliac artery end-to-side, two arteries(n = 15) | 4Internal iliac artery end-to-end, two arteries(n = 10) | ||||
| Day 1 urea(mg/dL) | Q1 - Q3 (Median) | 47–92 (67) | 50.3–92 (63) | 80–142 (109) | 62–161 (88) | 46–90 (67) | 79.3–135.5 (94) | 0.041* | 4 > 1. 2 |
| Mean ± SD | 69.76 ± 30.17 | 73.27 ± 33.86 | 110.33 ± 31.02 | 103.67 ± 51.33 | 68.93 ± 24.45 | 106.20 ± 39.35 | |||
| Day 7 urea(mg/dL) | Q1 - Q3 (Median) | 41–75.5 (57) | 47– 97.5 (69) | 47–120 (55) | 111–254 (125) | 52–81 (66) | 54.8–246.8 (165) | 0.017* | 4 > 1 |
| Mean ± SD | 62.87 ± 29.82 | 85.33 ± 55.42 | 74.00 ± 40.04 | 163.33 ± 78.83 | 71.47 ± 38.74 | 159.00 ± 105.67 | |||
| Day 30 urea(mg/dL) | Q1 - Q3 (Median) | 33.5–62.5 (46) | 40–61.8 (50) | 60–120 (62) | 59–103 (61) | 39–76 (57) | 42–77.5 (49) | 0.545 | - |
| Mean ± SD | 51.64 ± 25.29 | 54.83 ± 26.29 | 80.67 ± 34.08 | 74.33 ± 24.85 | 62.27 ± 35.57 | 56.67 ± 20.86 | |||
| Month 6 (mg/dL) | Q1 - Q3 (Median) | 1–1.4 (1.3) | 1.1–1.4 (1.3) | 1.3–1.5 (1.3) | 0.7–1.5 (1.3) | 1.2–1.6 (1.4) | 1.1–1.5 (1.3) | 0.209 | - |
| Mean ± SD | 1.24 ± 0.31 | 1.32 ± 0.37 | 1.33 ± 0.12 | 1.18 ± 0.39 | 1.43 ± 0.38 | 1.30 ± 0.37 | |||
| Year 1 urea(mg/dL) | Q1 - Q3 (Median) | 1–1.4 (1,1) | 1.1–1.5 (1.3) | 1.2–1.9 (1.5) | 0.8–1.3 (1.2) | 1.2–1.5 (1.3) | 1–1.6 (1,3) | 0.414 | - |
| Mean ± SD | 1.19 ± 0.33 | 1.34 ± 0.49 | 1.53 ± 0.32 | 1.08 ± 0.29 | 1.35 ± 0.34 | 1.25 ± 0.34 | |||
| Day 1 creatinine(mg/dL) | Q1 - Q3 (Median) | 1.9–3.8 (2.8) | 2.4–4.9 (3.3) | 4–7.1 (6.9) | 3.3–5.2 (3.5) | 2.4–7.3 (3.1) | 4.4–7.8 (5.5) | 0.002** | 4 > 1. 2 |
| Mean ± SD | 3.05 ± 1.36 | 4.01 ± 2.40 | 6.02 ± 1.73 | 3.98 ± 1.06 | 4.58 ± 3.23 | 5.93 ± 2.27 | |||
| Day 7 creatinine(mg/dL) | Q1 - Q3 (Median) | 1–1.6 (1.3) | 1.2–2.5 (1.6) | 1.1–6.4 (1.3) | 1.4 - 3.3 (2.4) | 1.3 - 1.8 (1.5) | 1.4 - 9.8 (5) | 0.001** | 4 > 1. 2 |
| Mean ± SD | 1.50 ± 0.92 | 2.40 ± 2.09 | 2.92 ± 3.02 | 2.37 ± 0.95 | 2.38 ± 3.17 | 5.57 ± 4.40 | |||
| Day 30 creatinine(mg/dL) | Q1 - Q3 (Median) | 0.9 - 1.5 (1.2) | 1 - 1.6 (1.3) | 1.1 - 2.3 (1.2) | 1.1–1.4 (1.1) | 1.1–1.8 (1.5) | 1–1.6 (1.4) | 0.101 | - |
| Mean ± SD | 1.23 ± 0.32 | 1.40 ± 0.65 | 1.53 ± 0.66 | 1.17 ± 0.17 | 2.27 ± 3.13 | 1.23 ± 0.46 | |||
| Month 6 creatinine(mg/dL) | Q1 - Q3 (Median) | 32–47.5 (41) | 30–45 (36) | 36–63 (50) | 31–50 (43) | 31.8–47.3 (40) | 36–53 (44) | 0.446 | - |
| Mean ± SD | 40.89 ± 13.13 | 38.72 ± 13.04 | 49.67 ± 13.5 | 41.33 ± 9.61 | 39.93 ± 8.78 | 45.67 ± 21.9 | |||
| Year 1 creatinine(mg/dL) | Q1 - Q3 (Median) | 30.5–47 (40) | 30–45 (37) | 36–75 (56) | 34–70 (42) | 27.5–40 (34.5) | 30–51 (45) | 0.201 | - |
| Mean ± SD | 39.67 ± 12.33 | 39.23 ± 14.32 | 55.67 ± 19.50 | 48.67 ± 18.90 | 35.43 ± 10.13 | 40.78 ± 13.09 | |||
| Renal artery blood flow velocity(cm/sec) | Q1 - Q3 (Median) | 114.5–219 (140) | 115–186.3 (130.5) | 80–290 (130) | 66–291.5 (190) | 116.5–322 (158.5) | 94.4–160 (137.5) | 0.446 | - |
| Mean ± SD | 179.26 ± 100.01 | 166.84 ± 90.79 | 166.67 ± 109.7 | 182.50 ± 112.94 | 216.25 ± 124.30 | 130.42 ± 36.69 | |||
| Resistive Index | Q1 - Q3 (Median) | 0.5–0.7 (0.6) | 0.6–0.7 (0.6) | 0.6–1 (0.6) | 0.7–0.8 (0.7) | 0.6–0.8 (0.6) | 0.6–0.7 (0.6) | 0.172 | - |
| Mean ± SD | 0.62 ± 0.11 | 0.63 ± 0.09 | 0.73 ± 0.24 | 0.75 ± 0.09 | 0.70 ± 0.12 | 0.65 ± 0.09 | |||
aKruskal–Wallis TestbBonferroni–Dunn Test